Haemophilus influenzae

Haemophilus influenzae
H. influenzae on a Chocolate agar plate.
Scientific classification
Domain:	Bacteria
Kingdom:	Eubacteria
Phylum:	Proteobacteria
Class:	Gammaproteobacteria
Order:	Pasteurellales
Family:	Pasteurellaceae
Genus:	Haemophilus
Species:	H. influenzae
Binomial name
Haemophilus influenzae (Lehmann & Neumann 1896) Winslow et al. 1917

Haemophilus influenzae satelliting colonies (pin point) near Staphylococcus aureus (yellow) on blood agar plate.

Haemophilus influenzae (formerly called Pfeiffer's bacillus or Bacillus influenzae) is a Gram-negative, coccobacillary, facultatively anaerobic capnophilic pathogenic bacterium of the family Pasteurellaceae. H. influenzae was first described in 1892 by Richard Pfeiffer during an influenza pandemic.^[1] He incorrectly described Haemophilus influenzae as the causative microbe, which retains "influenza" in its name.^[2][3]

The bacterium was argued by some to be the cause of influenza^[4] as bacterial influenza. H. influenzae is responsible for a wide range of localized and invasive infections, but influenza is caused by viruses.

This species was the first free-living organism to have its entire genome sequenced.^[5]

Serotypes[]

In 1930, two major categories of H. influenzae were defined: the unencapsulated strains and the encapsulated strains. Encapsulated strains were classified on the basis of their distinct capsular antigens. The six generally recognized types of encapsulated H. influenzae are: a, b, c, d, e, and f.^[6] Genetic diversity among unencapsulated strains is greater than within the encapsulated group. Unencapsulated strains are termed nontypable (NTHi) because they lack capsular serotypes; however, they can be classified by multilocus sequence typing. The pathogenesis of H. influenzae infections is not completely understood, although the presence of the polyribosyl ribitol phosphate (PRP) capsule in encapsulated type b (Hib), a serotype causing conditions such as epiglottitis, is known to be a major factor in virulence.^[7] Their capsule allows them to resist phagocytosis and complement-mediated lysis in the nonimmune host. The unencapsulated strains are almost always less invasive; they can, however, produce an inflammatory response in humans, which can lead to many symptoms. Vaccination with Hib conjugate vaccine is effective in preventing Hib infection but does not prevent infection with NTHi strains.^[8]

Most strains of H. influenzae are opportunistic pathogens; that is, they usually live in their host without causing disease, but cause problems only when other factors (such as a viral infection, reduced immune function or chronically inflamed tissues, e.g. from allergies) create an opportunity. They infect the host by sticking to the host cell using trimeric autotransporter adhesins.^[9]

Haemophilus influenzae type b (Hib) infection[]

Naturally acquired disease caused by H. influenzae seems to occur in humans only. In infants and young children, H. influenzae type b (Hib) causes bacteremia, pneumonia, epiglottitis and acute bacterial meningitis.^[10] On occasion, it causes cellulitis, osteomyelitis, and infectious arthritis. It is one cause of neonatal infection.^[11]

Due to routine use of the Hib vaccine in the U.S. since 1990, the incidence of invasive Hib disease has decreased to 1.3/100,000 in children.^[12] However, Hib remains a major cause of lower respiratory tract infections in infants and children in developing countries where the vaccine is not widely used. Unencapsulated H. influenzae strains are unaffected by the Hib vaccine and cause ear infections (otitis media), eye infections (conjunctivitis), and sinusitis in children, and are associated with pneumonia.^[13]

Diagnosis[]

Sputum Gram stain at 1000x magnification. The sputum is from a person with Haemophilus influenzae pneumonia, and the Gram negative coccobacilli are visible with a background of neutrophils.

Haemophilus influenzae requires X and V factors for growth. In this culture, Haemophilus has only grown around the paper disc that has been impregnated with X and V factors. No bacterial growth is seen around the discs that only contain either X or V factor.

Chest X-ray of a case of Haemophilus influenzae, presumably as a secondary infection from influenza. It shows patchy consolidations, mainly in the right upper lobe (arrow).

Chest X-ray in a case of COPD exacerbation where a nasopharyngeal swab detected Haemophilus influenzae: Opacities (on the patient's right side) can be seen in other types of pneumonia, as well.

Clinical features may include initial symptoms of an upper respiratory tract infection mimicking a viral infection, usually associated with fevers, often low-grade. This may progress to the lower respiratory tract in a few days, with features often resembling those of wheezy bronchitis. Sputum may be difficult to expectorate and is often grey or creamy in color. The cough may persist for weeks without appropriate treatment. Many cases are diagnosed after presenting chest infections that do not respond to penicillins or first-generation cephalosporins. A chest X-ray can identify alveolar consolidation.^[14]

Clinical diagnosis of H. influenzae is typically performed by bacterial culture or latex particle agglutinations. Diagnosis is considered confirmed when the organism is isolated from a sterile body site. In this respect, H. influenzae cultured from the nasopharyngeal cavity or sputum would not indicate H. influenzae disease, because these sites are colonized in disease-free individuals.^[15] However, H. influenzae isolated from cerebrospinal fluid or blood would indicate H. influenzae infection.

Culture[]

Bacterial culture of H. influenzae is performed on agar plates, the preferable one being chocolate agar, with added X (hemin) and V (nicotinamide adenine dinucleotide) factors at 37 °C in a CO₂-enriched incubator.^[16] Blood agar growth is only achieved as a satellite phenomenon around other bacteria. Colonies of H. influenzae appear as convex, smooth, pale, grey, or transparent colonies.^{[citation needed]}

Gram stained and microscopic observation of a specimen of H. influenzae will show Gram-negative coccobacillus. The cultured organism can be further characterized using catalase and oxidase tests, both of which should be positive. Further serological testing is necessary to distinguish the capsular polysaccharide and differentiate between H. influenzae b and nonencapsulated species.^{[citation needed]}

Although highly specific, bacterial culture of H. influenzae lacks sensitivity. Use of antibiotics prior to sample collection greatly reduces the isolation rate by killing the bacteria before identification is possible.^[17] Beyond this, H. influenzae is a finicky bacterium to culture, and any modification of culture procedures can greatly reduce isolation rates. Poor quality of laboratories in developing countries has resulted in poor isolation rates of H. influenzae.^{[citation needed]}

H. influenzae will grow in the hemolytic zone of Staphylococcus aureus on blood agar plates; the hemolysis of cells by S. aureus releases factor V which is needed for its growth. H. influenzae will not grow outside the hemolytic zone of S. aureus due to the lack of nutrients such as factor V in these areas. Fildes agar is best for isolation. In Levinthal medium, capsulated strains show distinctive iridescence.

Latex particle agglutination[]

The latex particle agglutination test (LAT) is a more sensitive method to detect H. influenzae than is culture.^[18] Because the method relies on antigen rather than viable bacteria, the results are not disrupted by prior antibiotic use. It also has the added benefit of being much quicker than culture methods. However, antibiotic sensitivity testing is not possible with LAT alone, so a parallel culture is necessary.^{[citation needed]}

Molecular methods[]

Polymerase chain reaction (PCR) assays have been proven to be more sensitive than either LAT or culture tests, and highly specific.^[18] However, PCR assays have not yet become routine in clinical settings. Countercurrent immunoelectrophoresis has been shown to be an effective research diagnostic method but has been largely supplanted by PCR.

Interaction with Streptococcus pneumoniae[]

Both H. influenzae and S. pneumoniae can be found in the upper respiratory system of humans. In an in vitro study of competition, S. pneumoniae always overpowered H. influenzae by attacking it with hydrogen peroxide and stripping off the surface molecules H. influenzae needs for survival.^[19]

When both bacteria are placed together into a nasal cavity, within 2 weeks, only H. influenzae survives. When either is placed separately into a nasal cavity, each one survives. Upon examining the upper respiratory tissue from mice exposed to both bacteria species, an extraordinarily large number of neutrophils (immune cells) was found. In mice exposed to only one of the species, the neutrophils were not present.

Lab tests showed neutrophils exposed to dead H. influenzae were more aggressive in attacking S. pneumoniae than unexposed neutrophils. Exposure to dead H. influenzae had no effect on live H. influenzae.

Two scenarios may be responsible for this response:

1. When H. influenzae is attacked by S. pneumoniae, it signals the immune system to attack the S. pneumoniae
2. The combination of the two species triggers an immune system response that is not set off by either species individually.

It is unclear why H. influenzae is not affected by the immune response.^[20]

Disease[]

Haemophilus influenzae can cause respiratory tract infections including pneumonia, otitis media, epiglottitis (swelling in the throat), eye infections and bloodstream infection, meningitis. It can also cause cellulitis (skin infection) and infectious arthritis (inflammation of the joint).^[21]

Treatment[]

Haemophilus influenzae produces beta-lactamases, and it is also able to modify its penicillin-binding proteins, so it has gained resistance to the penicillin family of antibiotics. In severe cases, cefotaxime and ceftriaxone delivered directly into the bloodstream are the elected antibiotics, and, for the less severe cases, an association of ampicillin and sulbactam, cephalosporins of the second and third generation, or fluoroquinolones are preferred. (Fluoroquinolone-resistant Haemophilus influenzae have been observed.)^[22]

Macrolides and fluoroquinolones have activity against non-typeable H. influenzae and could be used in patients with a history of allergy to beta-lactam antibiotics.^[23] However, macrolide resistance has also been observed.^[24]

Serious complications[]

The serious complications of HiB are brain damage, hearing loss, and even death.^[25]

Prevention[]

ActHIB (Hib-vaccine)

Effective vaccines for Haemophilus influenzae Type B have been available since the early 1990s, and are recommended for children under age 5 and asplenic patients. The World Health Organization recommends a pentavalent vaccine, combining vaccines against diphtheria, tetanus, pertussis, hepatitis B and Hib. There is not yet sufficient evidence on how effective this pentavalent vaccine is in relation to the individual vaccines.^[26]

Hib vaccines cost about seven times the total cost of vaccines against measles, polio, tuberculosis, diphtheria, tetanus, and pertussis. Consequently, whereas 92% of the populations of developed countries were vaccinated against Hib as of 2003, vaccination coverage was 42% for developing countries, and only 8% for least-developed countries.^[27]

The Hib vaccines do not provide cross-protection to any other Haemophilus influenzae serotypes like Hia, Hic, Hid, Hie or Hif.^[28]

An oral vaccination has been developed for non-typeable Haemophilus influenzae (NTHi) for patients with chronic bronchitis but it has not shown to be effective in reducing the number and severity of COPD exacerbations.^[29]

Sequencing[]

H. influenzae was the first free-living organism to have its entire genome sequenced. Completed by Craig Venter and his team at The Institute for Genomic Research, one of the institutes now part of the J. Craig Venter Institute. Haemophilus was chosen because one of the project leaders, Nobel laureate Hamilton Smith, had been working on it for decades and was able to provide high-quality DNA libraries. The genome of strain Rd KW20 consists of 1,830,138 base pairs of DNA in a single circular chromosome that contains 1604 protein-coding genes, 117 pseudogenes, 57 tRNA genes, and 23 other RNA genes.^[30] The sequencing method used was whole-genome shotgun, which was completed and published in Science in 1995.^[31]

Likely protective role of transformation[]

Unencapsulated H. influenzae is often observed in the airways of patients with chronic obstructive pulmonary disease (COPD). Neutrophils are also observed in large numbers in sputum from patients with COPD. The neutrophils phagocytize H. influenzae, thereby activating an oxidative respiratory burst.^[32] However instead of killing the bacteria the neutrophils are themselves killed (though such an oxidative burst likely causes DNA damage in the H. influenzae cells). Dearth of killing the bacteria appears to explain the persistence of infection in COPD.^[32]

H. influenzae mutants defective in the rec1 gene (a homolog of recA) are very sensitive to killing by the oxidizing agent hydrogen peroxide.^[33] This finding suggests that rec1 expression is important for H. influenzae survival under conditions of oxidative stress. Since it is a homolog of recA, rec1 likely plays a key role in recombinational repair of DNA damage. Thus H. influenzae may protect its genome against the reactive oxygen species produced by the host's phagocytic cells through recombinational repair of oxidative DNA damages.^[34] Recombinational repair of a damaged site of a chromosome requires, in addition to rec1, a second homologous undamaged DNA molecule. Individual H. influenzae cells are capable of taking up homologous DNA from other cells by the process of transformation. Transformation in H. influenzae involves at least 15 gene products,^[31] and is likely an adaptation for repairing DNA damage in the resident chromosome.^{[citation needed]}

Vaccines that target unencapsulated H. influenzae serotypes are in development.^[35]

See also[]

References[]

External links[]

Wikimedia Commons has media related to Haemophilus influenzae.

• Hib information on the World Health Organization (WHO) site.
• Fact sheet on the Centers for Disease Control and Prevention (CDC) site.
• Hib Initiative—from Johns Hopkins University, London School of Hygiene & Tropical Medicine, CDC & WHO
• November 2nd: World Pneumonia Day Website
• Centers for Disease Control and Prevention (2012). "Ch. 7: Haemophilus influenzae". In Atkinson W; Wolfe S; Hamborsky J (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (12th ed.). Washington, D.C.: Public Health Foundation. pp. 87–100. Archived from the original on 2017-03-10.
• "Haemophilus influenzae". NCBI Taxonomy Browser. 727.
• Type strain of Haemophilus influenzae at BacDive – the Bacterial Diversity Metadatabase